Governments have consistently approached change as a coordinated exercise, bundling multiple elements into single negotiations rather than adjusting one lever at a time. This pattern has shaped outcomes across pricing, pharmacy agreements, and the evolution of both off-patent and innovative medicine sectors, and it continues to define how the next phase of reform is likely to unfold.
Those who recognise and respond to the reality will be better positioned to shape reforms
March 31, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Most Australians want PBS medicine prices frozen or cut, poll finds
October 30, 2026 - - Latest News -
Canberra program shows young women where a future in health could take them
October 30, 2026 - - Latest News -
If only these patients needed a Spoodle, rather than a medicine
October 30, 2026 - - Latest News -
A hearing that provided more evidence of the need for meaningful change
October 29, 2026 - - Latest News -
Biotech sector warns R&D tax changes could drive clinical trials offshore
October 28, 2026 - - Latest News -
Rebates and net spend are the major PBS story of the past decade
October 28, 2026 - - Latest News -
Astellas bets up to US$1.34 billion on Melbourne startup's cancer candidate
October 28, 2026 - - Latest News
